Adult Dosing

Acute bacterial skin and skin structure infection (ABSSS)

• 200 mg IV infusion over 1 hour q24 hrs x 6 days

Note:

• Total time from reconstitution to administration should not exceed 24 hours at room temperature or under refrigeration at 2°C to 8°C (36°F to 46°F)
• Do not administer as an IV push or bolus
• Not for intra-arterial, IM, intrathecal, intraperitoneal, or SC administration

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by susceptible gram-positive bacteria

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

• Prescribing therapy in the absence of a proven suspected bacterial infection may increase the risk of the development of drug-resistant bacteria
• Alternative therapy should be considered in treating patients with neutropenia and acute bacterial skin and skin structure infection as the safety and efficacy of tedizolid have not been evaluated in patients with neutropenia
• Therapy can alter the normal flora of the colon and may cause overgrowth of C.difficile contributing to the development of mild to fatal Clostridium difficile-associated diarrhea (CDAD)
• C. difficile produces toxins A and B which contribute to CDAD. Hypertoxin producing strains causes increased morbidity and mortality since these infections can be refractory to antibiotic therapy and may require colectomy
• Consider CDAD in all the patients who present with diarrhea following antibiotic use
• If CDAD suspected or confirmed discontinue the therapy and provide fluid, electrolyte, and protein supplementation along with antibiotics for C. difficile and surgical evaluation as needed to the patient

Pregnancy Category:C

Breastfeeding: Tedizolid is excreted in rat milk, but it is unknown whether it is excreted in human milk. Manufacturer advises caution.

• CV: Palpitation, tachycardia, hypertension
• CNS: Headache, dizziness
• NEURO: Hypoesthesia, paraesthesia, VIIth nerve paralysis
• PSYCHIATRIC: Insomnia
• GI: Clostridium difficile colitis, oral candidiasis, nausea, diarrhea, vomiting
• GU: Vulvovaginal mycotic infection
• HEMA: Anemia
• DERM: Pruritus, urticaria, dermatitis
• EENT: Asthenopia, vision blurred, visual impairment, vitreous floaters
• HYPERSENSITIVITY: Drug Hypersensitivity
• MISC: Infusion-related reactions
• LABTEST: Decreased white blood count, increased hepatic transaminase

• Oxazolidione antibiotic; activity is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis
• Bioavailability: 91% (PO and IV); no dosage adjustment is needed between IV and oral administration
• Metabolized by liver; CYP450: unknown
• Excretion: 82% feces; 18% urine
• Half-life: 12 hours

US Trade Name(s)

• Sivextro

US Availability

Sivextro

• PWDR for INJ: 200 mg/vial

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Antimicrobials

Antibiotics

oxazolidinone

Dermatologic

Antibiotics

oxazolidinone